계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Apitope
company
About
Apitope is a European biotech company
- 11 - 50
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- €10M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2002
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Apitope is a biotech company focused on the discovery and development of disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis. The company, whose first product candidate is licensed to Merck Serono, will now progress its remaining portfolio of product candidates developed with its proprietary platform technology.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
€22M
Apitope has raised a total of
€22M
in funding over 2 rounds. Their latest funding was raised on
Sep 29, 2015 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 29, 2015 | Series B | €12M | 1 | — | — | Detail |
| Oct 30, 2008 | Series A | €10M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Apitope is funded by 2 investors.
Wyvern Seed Fund
and Vinnof
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Wyvern Seed Fund
|
— | Series B |
Vinnof
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
